Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. - Kuhn,D.J.; Chen,Q.; Voorhees,P.M.; Strader,J.S.; Shenk,K.D.; Sun,C.M.; Demo,S.D.; Bennett,M.K.; van Leeuwen,F.W.; Chanan-Khan,A.A.; Orlowski,R.Z. (Blood, 2007)